Zheng Wang, Clinical Assistant Professor at Ruijin Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, shared on LinkedIn:
“Recently, our new research titled ‘Clinicopathological and molecular significance of HER2-low expression in Asian women with triple-negative breast cancer’ has been published in Therapeutic Advances in Medical Oncology.
This study is aimed to assess the clinicopathological and molecular characteristics of HER2-low triple-negative breast cancer (TNBC) in Asian women. HER2-low was associated with a higher percentage of postmenopausal status, lymph node positivity, and invasive ductal carcinoma histology.
HER2-low group had less BRCA1 mutation but was associated with a higher rate of PIK3CA mutation compared with HER2-zero TNBC. No significant difference in breast pathologic complete response rate, breast cancer-free interval, or overall survival was observed between HER2-low and HER2-zero TNBC.
Our results show that HER2-low TNBC had specific clinicopathological, genomic profiling, and biological features compared with HER2-zero TNBC in Asian women, but without significant differences in treatment response and prognosis, warranting exploring better treatment strategies to improve disease outcomes.”
Authors: Cuiyan Yang, Haoyu Wang, Yiwei Tong, Zheng Wang, Xi Sun, Anqi Li, Yujie Lu, Mengyuan Han, Siji Zhu, Lei Dong, Kunwei Shen, and Xiaosong Chen
More posts featuring Zheng Wang.